Category: basic life sciences retractions

Data were “fraudulently obtained” in epilepsy paper, probe finds

brain-research-bulletinA brain research journal has retracted a 2016 study about epilepsy after an institutional investigation determined that some of the data were taken from another published paper.

The retraction notice for the study — which appeared in Brain Research Bulletin — cites an investigation by the scientific integrity committee at Tongji University in Shanghai, China, which concluded the authors had engaged in “unethical publishing behavior.”

Here’s the retraction notice for “Clc-2 knockout attenuated experimental temporal lobe epilepsy in mice by tonic inhibition mediated by GABAA receptors:” Continue reading Data were “fraudulently obtained” in epilepsy paper, probe finds

Author asks to retract nearly 20-year old paper over figure questions, lack of data

journal-of-biological-chemistryThe last author of a 1999 paper has asked the journal to retract it less than one month after a user raised questions about images on PubPeer.

Yesterday, last author Jim Woodgett posted a note on the site saying the author who generated the figures in question could not find the original data, and since he agreed the images appeared “suspicious,” he had contacted the journal to retract the paper.

Here’s the note from Woodgett, based at Lunenfeld-Tanenbaum
Research Institute at Mount Sinai Hospital in Toronto: Continue reading Author asks to retract nearly 20-year old paper over figure questions, lack of data

Amid controversial Sarepta approval decision, FDA head calls for key study retraction

FDAThe head of the U.S. Food and Drug Administration (FDA) has called for the retraction of a study about a drug that the agency itself approved earlier this week, despite senior staff opposing the approval.

On September 19, the FDA okayed eteplirsen to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder that results in muscle degeneration and premature death. Several of its top officials disagreed with the drug’s approval, questioning how beneficial it will be for patients, as Forbes, MedPage Today and others reported.

In a lengthy report Commissioner Robert Califf sent to senior FDA officials on September 16 — that was made public on September 19 — he called for the retraction of a 2013 study published in Annals of Neurology funded by the seller of eteplirsen, which showed beneficial effects of the drug in DMD patients. Califf writes in the report:

Continue reading Amid controversial Sarepta approval decision, FDA head calls for key study retraction

Researcher in Ireland loses two 13-year old studies

journal-of-biological-chemistryThe Journal of Biological Chemistry (JBC) has retracted two 2003 studies after concluding that figures in the papers had been duplicated, and portions of some figures in one paper “did not accurately represent the results of the experimental conditions.”

The two newly retracted papers have the same last author — Therese Kinsella, a biochemist at the University College Dublin (UCD), who told us the data have been upheld by subsequent research, but that she supports the retractions, which are now part of a UCD investigation.

The retractions will bring up some familiar names: The first author on one of the papers is Sinéad Miggin from Maynooth University in the Republic of Ireland; in 2014, Miggin logged two retractions in the JBC, which triggered an investigation into co-author Aisha Qasim Butt. Last year, Maynooth University revoked Butt’s PhD after she admitted to “falsification and misrepresentation” of data in both studies as well as her PhD thesis. At the time, Miggin and two other researchers were fully exonerated by Maynooth University from “any wrongdoing.”

Butt, however, is not an author of either of the newly retracted papers. Although Butt’s LinkedIn page still lists her as a postdoctoral researcher at UCD, a spokesperson from the institution told us she is no longer based there.

We don’t often see such old papers retracted. Kaoru Sakabe, Manager of Publishing Issues at the American Society for Biochemistry and Molecular Biology, which publishes JBC, told us how this decision came about: Continue reading Researcher in Ireland loses two 13-year old studies

Authors retract 2016 cancer study when data don’t align with figures

cell-death-and-differentiationResearchers have retracted a 2016 cancer study, citing discrepancies between the data and images presented in the paper. 

Although the retraction notice itself contains relatively little information, we’ve obtained a letter from the last author — Jun-Li Luo of The Scripps Research Institute in Jupiter, Florida — to the editor-in-chief of Cell Death and Differentiation that says a bit more. 

According to the letter, after receiving the anonymous email, Luo conducted an investigation, contacting co-authors who contributed each of the figures in question. Although Luo writes that he has no reason to suspect fraud, the researchers were not able to provide some of the original data.

PubPeer commenters have questioned figures 1, 3, 4, 5, 6 and 7 in the study, “IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy.”

In the letter, Luo tells Gerry Melino, co-editor-in-chief of the journal from the University of Leicester, UK, that figures 3D and 3E were provided by the study’s first author, Xing Fang, adding: Continue reading Authors retract 2016 cancer study when data don’t align with figures

When does “overlap” become plagiarism? Here’s what PLOS ONE decided

PLOSOne

Consider this: Fragments of a PLOS ONE paper overlap with pieces of other publications. The authors used them without credit and without quotation marks.

This sounds an awful lot like plagiarism — using PLOS‘s own standards, even. But the journal isn’t calling it plagiarism. They’ve labeled this an instance of “text overlap,” a spokesperson told us, based on the amount of material that the paper shares with others.

The last author — Carlo Croce, who has two retractions under his belt — denies that he plagiarized, and says that his university has cleared him of a plagiarism charge from an anonymous whistleblower.

PLOS fixed this case last year with a correction notice — not the common course of action for a case of confirmed plagiarism. Take a look at the notice for yourself:

Continue reading When does “overlap” become plagiarism? Here’s what PLOS ONE decided

Spanish lab admits to image manipulation, retracts one paper, corrects another

JBCA group has retracted one paper and corrected another in the Journal of Biological Chemistry (JBC) for image manipulations.

Last author José G. Castaño told us the manipulation occurred at the Universidad Autónoma de Madrid, where he and one other co-author are based. He declined to name who was responsible.

Here’s the retraction notice for “Cytomegalovirus promoter up-regulation is the major cause of increased protein levels of unstable reporter proteins after treatment of living cells with proteasome inhibitors:”

Continue reading Spanish lab admits to image manipulation, retracts one paper, corrects another

Swiss, French institutions investigating several papers

eth-zurichcnrsInstitutions in France and Switzerland are investigating figures in several molecular biology papers, according to a joint press release published today.

Unfortunately, there’s not much more we can tell you about the investigation — the press release doesn’t specify the names of researchers, journals, or even the area within molecular biology that’s under scrutiny.

The National Center for Scientific Research (CNRS) in France will lead the inquiry, with contribution from ETH Zürich in Switzerland. Molecular biology researchers from both institutions were involved in the flagged publications, an ETH Zürich spokesperson told us.

The ETH Zürich spokesperson added: Continue reading Swiss, French institutions investigating several papers

Authors didn’t generate key brain images, probe finds

Frontiers in Human NeuroscienceA neuroscience journal has issued a retraction after discovering some of the paper’s integral images didn’t originate from the authors’ labs.

The retraction notice  — for a study about a condition once known as “water on the brain” — cites an investigation by the journal’s publisher, Frontiers, which determined that the figures were not “duly attributed.” The authors say they agree with the retraction.  

Here’s the retraction notice for “Revisiting hydrocephalus as a model to study brain resilience,” published by Frontiers in Human Neuroscience: Continue reading Authors didn’t generate key brain images, probe finds

Biologist loses second paper — again, for unvalidated figures

Cellular SignallingA researcher at Case Western Reserve University in Ohio has retracted a second paper after a review found the figures didn’t match the original data.  

Last year, we reported on a previous retraction of a paper co-authored by biologist Alan Levine in Inflammatory Bowel Diseases, which was pulled for the exact same reason; even the retraction notices use similar language. The first author on both papers is Debasmita Mandal, also listed at Case Western Reserve University.

Here’s the retraction notice for “REDOX regulation of IL-13 signaling in intestinal epithelial cells: usage of alternate pathways mediates distinct gene expression patterns,” published by Cellular Signalling: Continue reading Biologist loses second paper — again, for unvalidated figures